San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.”
The study produced a long-term health economic analysis using the IQVIA CORE Diabetes Model. This allows the calculation of long-term outcomes based on the best data currently available. It establishes the cost-effectiveness for funding Dexcom rtCGM technology against testing with fingerprints.
According to Dexcom, the analysis suggests that rtCGM use results in significant improvements in HbA1c. It also demonstrated reductions in long-term diabetes-related complications and emergency department visits.
Get the full story at our sister site, Drug Delivery Business News.